To read the full article sign up for free or sign in.

FDA issues CRL for Telix’s kidney cancer imaging agent

Sep. 2, 2025

Telix Pharmaceuticals Ltd. received an FDA complete response letter (CRL) a day after the Aug. 27 PDUFA date for its BLA for radiopharmaceutical renal cancer imaging agent, Zircaix (TLX250-CDx, 89Zr-DFO-girentuximab).

BioWorld Asia Regulatory Diagnostics Cancer Antibody Asia-Pacific Australia U.S. FDA

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent

BioWorld Science

Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...